Statistiche di base
| LEI | 549300W8GPUWU8QNU293 |
| CIK | 1651311 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Merus N.V.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exact nam |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2025 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organization) |
|
| June 5, 2025 |
5,263,158 Shares Merus N.V. Common Shares 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-277465 PROSPECTUS SUPPLEMENT (to Prospectus dated February 28, 2024) 5,263,158 Shares Merus N.V. Common Shares We are offering 5,263,158 common shares. Our common shares are listed on The Nasdaq Global Market under the symbol “MRUS.” On June 3, 2025, the last reported sale price of our common shares on The Nasdaq Global Market was $62.42 |
|
| June 5, 2025 |
Exhibit 1.1 Merus N.V. 5,263,158 Common Shares (nominal value €0.09 per share) Underwriting Agreement New York, New York June 3, 2025 Jefferies LLC BofA Securities, Inc. Leerink Partners LLC Guggenheim Securities, LLC Truist Securities, Inc. As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o BofA Securities, Inc. One Bryant Park New Yor |
|
| June 5, 2025 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables S-3 Merus N.V. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fe |
|
| June 3, 2025 |
SUBJECT TO COMPLETION, DATED JUNE 3, 2025 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277465 SUBJECT TO COMPLETION, DATED JUNE 3, 2025 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospec |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2025 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organization) |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2025 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organization) |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exact na |
|
| May 7, 2025 |
Exhibit 10.1 [*] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. Execution Version LICENSE AGREEMENT BY AND BETWEEN Merus N.V. AND Partner Therapeutics, Inc. Table of Contents Page Article 1 DEFINITIONS 1 Article 2 LICENSE |
|
| April 24, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 14, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| April 7, 2025 |
Insider Trading Compliance Policy Exhibit 19.1 MERUS N.V. INSIDER TRADING COMPLIANCE POLICY (As of March 19, 2025) This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: • Section I provides an overview; • Section II sets forth the policies of the Company prohibiting insider trading; • Section III explains insider trading; • Section IV consists of procedures that have been put in place by the Company to |
|
| February 27, 2025 |
Merus N.V. 2016 Incentive Award Plan Amended and Restated May 7, 2024 Exhibit 10.1.1 MERUS N.V. 2016 INCENTIVE AWARD PLAN (As Amended and Restated Effective May 7, 2024) ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defin |
|
| February 27, 2025 |
License Agreement by and between Merus N.V. and Partner Therapeutics, Inc. dated November 27, 2024 Exhibit 10.4.6 Execution Version LICENSE AGREEMENT BY AND BETWEEN Merus N.V. AND Partner Therapeutics, Inc. Table of Contents Page Article 1 DEFINITIONS 1 Article 2 LICENSES AND OTHER RIGHTS 13 Article 3 GOVERNANCE 15 Article 4 TECHNOLOGY TRANSFER AND REGULATORY TRANSFER 17 Article 5 DEVELOPMENT AND COMMERCIALIZATION 19 Article 6 FINANCIAL TERMS 25 Article 7 IP OWNERSHIP, INVENTIONS, PATENT PROSEC |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) c ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37773 MERUS N.V. |
|
| February 27, 2025 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of May 7, 2024, Merus N.V. (the “Company,” “we,” “us,” and “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares. Set forth below is a summary of certain information concerning o |
|
| February 10, 2025 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Merus N.V. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the S |
|
| December 16, 2024 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 4, 2024 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organizati |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 27, 2024 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organizat |
|
| November 14, 2024 |
MRUS / Merus N.V. / SAMLYN CAPITAL, LLC Passive Investment SC 13G/A 1 d1150424313g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Merus N.V. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 14, 2024 |
MRUS / Merus N.V. / Flynn James E Passive Investment SC 13G/A 1 e664009sc13ga-merus.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3) * Merus N.V. (Name of Issuer) Common Shares (Title of Class of Securities) N5749R100 (CUSIP Number) September 30, 2024 (Da |
|
| November 14, 2024 |
MRUS / Merus N.V. / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Merus N.V. (Name of Issuer) Common shares, €0.09 nominal value per share (Title of Class of Securities) N5749R100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 14, 2024 |
MRUS / Merus N.V. / RTW INVESTMENTS, LP - MERUS N.V. Passive Investment SC 13G 1 p24-3252sc13g.htm MERUS N.V. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Merus N.V. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box t |
|
| November 14, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-3252exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2024 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organizati |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exac |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exact nam |
|
| August 1, 2024 |
Articles of Association of Merus N.V., as amended on July 29, 2024 Exhibit 3.1 1 This is a translation into English of the official Dutch version of the deed of amendment to the articles of association of a limited liability company under Dutch law. Definitions included in Article 1 below appear in the English alphabetical order in the official Dutch version. In the event of a conflict between the English and Dutch texts, the Dutch text shall prevail. ARTICLES OF |
|
| July 24, 2024 |
MRUS / Merus N.V. / INCYTE CORP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MERUS N.V. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) June 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| July 1, 2024 |
Separation Agreement and Release, by and between Merus US, Inc. and Andrew Joe. Exhibit 10.3 Separation Agreement and Release This Separation Agreement and Release (“Agreement”) is made by and between A. Joe (“Executive”) and Merus US, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Employment Agreement (as defined below) |
|
| July 1, 2024 |
Separation Agreement and Release, by and between Merus US, Inc. and Hui Liu. Exhibit 10.2 Separation Agreement and Release This Separation Agreement and Release (“Agreement”) is made by and between H. Liu (“Executive”) and Merus US, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Employment Agreement (as defined below) |
|
| July 1, 2024 |
Employment Agreement by and between Merus US, Inc. and Fabian Zohren. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated as of June 30, 2024, is made by and between Merus US, Inc., a Delaware corporation (together with any successors or assigns, the “Company”), and F. Zohren (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). RECITALS (A) It is the desire of the Company to assu |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2024 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organization) |
|
| July 1, 2024 |
Consultancy Agreement, by and between Merus N.V. and Andrew Joe. Exhibit 10.4 Merus N.V. Uppsalalaan 17 3rd and 4th floor 3584 CT Utrecht The Netherlands www.merus.nl KvK Utrecht 30.189.136 BTW NL8122.47.413.B01 Execution Copy CONSULTANCY AGREEMENT This Consultancy Agreement (“Agreement”) is effective as of July 1, 2024, (the “Effective Date”) and is entered into by and between: (1) Merus N.V., a public company with limited liability (naamloze vennootschap), ha |
|
| May 30, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Merus N.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwa |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 29, 2024 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organization) |
|
| May 30, 2024 |
Exhibit 1.1 Merus N.V. 7,550,000 Common Shares (nominal value €0.09 per share) Underwriting Agreement New York, New York May 29, 2024 Jefferies LLC BofA Securities, Inc. Leerink Partners LLC Guggenheim Securities, LLC BMO Capital Markets Corp. As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o BofA Securities, Inc. One Bryant Park New Y |
|
| May 30, 2024 |
7,550,000 Shares Merus N.V. Common Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277465 PROSPECTUS SUPPLEMENT (to Prospectus dated February 28, 2024) 7,550,000 Shares Merus N.V. Common Shares We are offering 7,550,000 common shares. Our common shares are listed on The Nasdaq Global Market under the symbol “MRUS.” On May 29, 2024, the last reported sale price of our common shares on The Nasdaq Global Market |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 28, 2024 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organization) |
|
| May 28, 2024 |
SUBJECT TO COMPLETION, DATED MAY 28, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277465 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and accompanying prospectus are n |
|
| May 10, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporatio |
|
| May 8, 2024 |
301144389 v2 exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION, OPTION and License Agreement This Collaboration, Option and License Agreement (the “Agreement”), effective as of March 5, |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organization) ( |
|
| May 8, 2024 |
Articles of Association of Merus N.V., as amended on May 7, 2024 Exhibit 3.1 1 This is a translation into English of the official Dutch version of the articles of association of a limited liability company under Dutch law. Definitions included in Article 1 below appear in the English alphabetical order, but will appear in the Dutch alphabetical order in the official Dutch version. In the event of a conflict between the English and Dutch texts, the Dutch text sh |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exact na |
|
| May 8, 2024 |
Consulting Agreement, dated April 15, 2024 between Victor Sandor and Merus US, Inc. Exhibit 10.2 CONSULTANCY AGREEMENT This Consultancy Agreement (“Agreement”) is effective as of April 15, 2024 (the “Effective Date”) and is entered into by and between: (1) Merus US, Inc., a Delaware corporation (“Merus”); and (2) Victor Sandor, M.D. (“Consultant”); (Each of Merus and Consultant may hereinafter be referred to as a “Party” or collectively referred to as the “Parties.”) WHEREAS: (A) |
|
| April 25, 2024 |
1271 Avenue of the Americas New York, New York 10020-1401 Tel: +1.212.906.1200 Fax: +1.212.751.4864 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County April 25, 2024 Century City Paris Chicago Riyadh Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul VIA EDGAR Hamburg Silicon Valley Hong Kong Singapore United States Securities and Exchange |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 10, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 25, 2024 |
MRUS / Merus N.V. / INCYTE CORP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MERUS N.V. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) March 25, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 6, 2024 |
MRUS / Merus N.V. / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6*) MERUS, N.V. (Name of Issuer) COMMON STOCK (Title of Class of Securities) N5749R100 (CUSIP Number) February 29, 2024 (Date of Event Which Requires Filing of this Statement |
|
| February 28, 2024 |
Exhibit 4.1 MERUS N.V. INDENTURE Dated as of [ ], 20[ ] [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. Establ |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) c ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37773 MERUS N.V. (E |
|
| February 28, 2024 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM February 28, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Merus N.V., a public limited liability company incorporated under the laws of the Netherlands (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principa |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Merus N.V. (Exact name of Registrant as Specified in Its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common shares, nominal value €0.0 |
|
| February 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Merus N.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward |
|
| February 28, 2024 |
Exhibit 97.1 MERUS N.V. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Merus N.V. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of September 27, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy This Policy shall |
|
| February 14, 2024 |
MRUS / Merus N.V. / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
MRUS / Merus N.V. / SAMLYN CAPITAL, LLC Passive Investment SC 13G 1 d1093027713g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Merus N.V. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 14, 2024 |
SC 13G/A 1 sc13ga1107422mrus02142024.htm AMENDMENT NO. 11 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 11)1 Merus N.V. (Name of Issuer) Common Shares, nominal value €0.09 |
|
| February 12, 2024 |
MRUS / Merus N.V. / Flynn James E Passive Investment SC 13G/A 1 e619255sc13ga-merus.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * Merus N.V. (Name of Issuer) Common Shares (Title of Class of Securities) N5749R100 (CUSIP Number) December 31, 2023 (Dat |
|
| February 8, 2024 |
MRUS / Merus N.V. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Merus N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N5749R100 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| January 18, 2024 |
MRUS / Merus N.V. / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 mrus1572-form.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5*) MERUS, N.V. (Name of Issuer) COMMON STOCK (Title of Class of Securities) N5749R100 (CUSIP Number) December 31, 2023 (Date of Event Which Requ |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exac |
|
| August 14, 2023 |
MRUS / Merus N.V / INCYTE CORP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Merus n.v. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) Maria E. Pasquale Executive Vice President and General Counsel Incyte Corporation 1801 Augustine Cut-Off, Wilmington, Delawar |
|
| August 11, 2023 |
EX-1.1 Exhibit 1.1 Execution Version Merus N.V. 6,818,182 Common Shares (nominal value €0.09 per share) Underwriting Agreement New York, New York August 9, 2023 Jefferies LLC BofA Securities, Inc. Guggenheim Securities, LLC William Blair & Company, L.L.C. As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o BofA Securities, Inc. One Bryan |
|
| August 11, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2023 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organization |
|
| August 11, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Merus N.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwa |
|
| August 11, 2023 |
6,818,182 Shares Merus N.V. Common Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255903 PROSPECTUS SUPPLEMENT (to Prospectus dated May 7, 2021) 6,818,182 Shares Merus N.V. Common Shares We are offering 6,818,182 common shares. Our common shares are listed on The Nasdaq Global Market under the symbol “MRUS.” On August 9, 2023, the last reported sale price of our common shares on The Nasdaq Global Mark |
|
| August 9, 2023 |
SUBJECT TO COMPLETION, DATED AUGUST 9, 2023 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255903 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and accompanying prospectus are n |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exact nam |
|
| June 15, 2023 |
Employment Agreement, dated as of June 14, 2023, by and between Merus US, Inc. and Gregory Perry EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated as of June 14, 2023, is made by and between Merus US, Inc., a Delaware corporation (together with any successors or assigns, the “Company”), and Gregory Perry (the “Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). RECITALS (A) It is the desire of the |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2023 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organization) |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2023 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organization) |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exact na |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 18, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 14, 2023 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organization |
|
| March 10, 2023 |
MRUS / Merus N.V / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 form919.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4*) MERUS, N.V. (Name of Issuer) COMMON STOCK (Title of Class of Securities) N5749R100 (CUSIP Number) February 28, 2023 (Date of Event Which Requires F |
|
| February 28, 2023 |
February 28, 2023 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) c ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37773 MERUS N.V. (E |
|
| February 28, 2023 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2021, Merus N.V. (the “Company,” “we,” “us,” and “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares. Set forth below is a summary of certain information concer |
|
| February 28, 2023 |
EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated as of February 24, 2023 (“Effective Date”), is made by and between Merus US, Inc. |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 10)1 Merus N.V. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) December |
|
| February 14, 2023 |
MRUS / Merus N.V. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SC 13G/A 1 tm234999d1sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 2)* Merus N.V. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2023 |
MRUS / Merus N.V. / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2023 |
MRUS / Merus N.V. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 6, 2023 |
MRUS / Merus N.V. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Merus N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N5749R100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 1, 2023 |
MRUS / Merus N.V. / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) MERUS, N.V. (Name of Issuer) COMMON STOCK (Title of Class of Securities) N5749R100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement |
|
| January 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organizatio |
|
| January 9, 2023 |
Corporate Presentation January 2023 Exhibit 99.1 Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation) (Commission F |
|
| January 6, 2023 |
Employment Agreement, dated January 1, 2023, by and between Merus US, Inc. and Peter Silverman Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated as of January 1, 2022 (“Effective Date”), is made by and between Merus US, Inc., a Delaware corporation (together with any successors or assigns, the “Company”), and Peter B. Silverman (the “Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). RECITALS (A) Merus |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exac |
|
| September 30, 2022 |
MRUS / Merus N.V. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exact nam |
|
| May 31, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2022 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organization) |
|
| May 16, 2022 |
MRUS / Merus N.V. / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 9, 2022 |
Informal translation dated 2 May 2022 RIDER LEASE AGREEMENT Exhibit 10.1 to LEASE OF OFFICE ACCOMMODATION and other commercial accommodation within the meaning of article 7:230a of the Dutch Civil Code SIGNATORIES Kadans Science Partner XIII B.V., having its registered office in 5076 PB Haaren at Rijksweg 5, registered in the trade register under number 73038954, hereafter referred to as 'Lessor', |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exact na |
|
| May 9, 2022 |
Informal translation dated 2 May 2022 2th RIDER LEASE AGREEMENT Exhibit 10.2 to LEASE OF OFFICE ACCOMMODATION and other commercial accommodation within the meaning of article 7:230a of the Dutch Civil Code SIGNATORIES Kadans Science Partner XIII B.V., having its registered office in (5076 PB) Haaren at Rijksweg 5, registered in the trade register under number 73038954, hereafter referred to as 'Le |
|
| April 29, 2022 |
DEF 14A 1 d281160ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the app |
|
| April 19, 2022 |
PRE 14A 1 d281160dpre14a.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the app |
|
| February 28, 2022 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2021, Merus N.V. (the ?Company,? ?we,? ?us,? and ?our?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares. Set forth below is a summary of certain information concer |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37773 MERUS N.V. (Exa |
|
| February 14, 2022 |
MRUS / Merus N.V. / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) MERUS, N.V. (Name of Issuer) COMMON STOCK (Title of Class of Securities) N5749R100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 9)1 Merus N.V. (Name of Issuer) Common Shares, nominal value ?0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) December |
|
| February 14, 2022 |
MRUS / Merus N.V. / Boxer Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Merus N.V. (Name of Issuer) Common shares, nominal value ?0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 4, 2022 |
MRUS / Merus N.V. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Merus N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N5749R100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 25, 2022 |
Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to Exhibit 99.1 Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145 UTRECHT, The Netherlands and CAMBRIDGE, Mass., January 25, 2022 (GLOBE NEWSWIRE) ? Merus N.V. (Nasdaq: MRUS) (?Merus?, ?the Company?, ?we?, or ?our?), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics? and Triclonics?), today annou |
|
| January 25, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 25, 2022 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organizati |
|
| November 8, 2021 |
Exhibit 1.1 Merus N.V. 3,859,650 Common Shares (nominal value ?0.09 per share) Underwriting Agreement New York, New York November 4, 2021 Jefferies LLC SVB Leerink LLC As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o SVB Leerink LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 Ladies and Gentlemen: Merus N.V., a public limi |
|
| November 8, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255903 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Maximum Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2) Common shares, nominal value ?0.09 per share 4,438,597 $28.50 $126,500,015 $11,727 (1) Assumes exercise in full of |
|
| November 8, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2021 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organizati |
|
| November 4, 2021 |
SUBJECT TO COMPLETION, DATED NOVEMBER 4, 2021 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255903 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and accompanying prospe |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exac |
|
| November 2, 2021 |
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). |
|
| August 10, 2021 |
MRUS / Merus N.V. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Merus N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N5749R100 (CUSIP Number) July 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| August 5, 2021 |
Exhibit 10.3.4 AMENDMENT 1 TO LEASE OF OFFICE SPACE AND LABORATORY SPACE This amendment (?Amendment 1?) is made effective as of June 3, 2021 and applies to two agreements for the Lease Of Office Space And Laboratory Space, the first executed November 30, 2016 and the second executed March 29, 2018 between Stichting Incubator Utrecht (?Lessor?) and Merus N.V. (?Lessee?). Either Lessor or Lessee may |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exact nam |
|
| July 7, 2021 |
MRUS / Merus N.V. / BIOTECHNOLOGY VALUE FUND L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 8)1 Merus N.V. (Name of Issuer) Common Shares, nominal value ?0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) July 2, 2 |
|
| May 28, 2021 |
Articles of Association of Merus N.V., as amended on May 28, 2021 Exhibit 3.1 1 This is a translation into English of the official Dutch version of the articles of association of a limited liability company under Dutch law. Definitions included in Article 1 below appear in the English alphabetical order, but will appear in the Dutch alphabetical order in the official Dutch version. In the event of a conflict between the English and Dutch texts, the Dutch text sh |
|
| May 28, 2021 |
Articles of Association of Merus N.V., as amended on May 28, 2021, marked to show amendments. Exhibit 3.2 This is a translation into English of the official Dutch version of the articles of association of a limited liability company under Dutch law. Definitions included in Article 1 below appear in the English alphabetical order, but will appear in the Dutch alphabetical order in the official Dutch version. In the event of a conflict between the English and Dutch texts, the Dutch text shal |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 28, 2021 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organization) |
|
| May 7, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on May 7, 2021 Registration No. |
|
| May 7, 2021 |
Open Market Sale Agreement, dated as of May 7, 2021, by and between Merus N.V. and Jefferies LLC. Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM May 7, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Merus N.V., a public limited liability company incorporated under the laws of the Netherlands (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the |
|
| May 7, 2021 |
Exhibit 4.1 MERUS N.V. INDENTURE Dated as of [ ], 20[ ] [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. Establishm |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exact na |
|
| April 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 19, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37773 MERUS N.V. (Exa |
|
| March 16, 2021 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2020, Merus N.V. (the ?Company,? ?we,? ?us,? and ?our?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares. Set forth below is a summary of certain information concer |
|
| March 16, 2021 |
As filed with the Securities and Exchange Commission on March 16, 2021 Registration No. |
|
| March 16, 2021 |
Exhibit 10.4.5 EXECUTION VERSION COLLABORATION AND LICENSE AGREEMENT between ELI LILLY AND COMPANY and MERUS N.V. [*] Certain information in this document has been omitted as the information is not material and would be competitively harmful if publicly disclosed. Table of Contents Page Article 1 DEFINITIONS1 Article 2 GOVERNANCE AND JOINT STEERING COMMITTEE18 2.1 Alliance Managers18 2.2 Project M |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Merus N.V. (Name of Issuer) Common Shares, €0.09 nominal value per share (Title of Class of Securities) N5749R100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 12, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) MERUS, N.V. (Name of Issuer) COMMON STOCK (Title of Class of Securities) N5749R100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 7)1 Merus N.V. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) December |
|
| February 11, 2021 |
EX-99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each |
|
| February 11, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Merus N.V. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| January 28, 2021 |
S-3MEF As filed with the Securities and Exchange Commission on January 28, 2021 Registration No. |
|
| January 28, 2021 |
AW MERUS N.V. Yalelaan 62 3584 CM Utrecht The Netherlands January 28, 2021 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: Withdrawal of Amendment to Registration Statement on Form S-3 (File No. 333-252282) Dear Mr. Buchmiller: Merus N.V. (the “Company”) hereby requests that the amendment |
|
| January 25, 2021 |
Under the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Merus n.v. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) Maria E. Pasquale Executive Vice President and General Counsel Incyte Corporation 1801 Augustine Cut-Off, Wilmington, Delawar |
|
| January 22, 2021 |
4,848,485 Shares Merus N.V. Common Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-233367 PROSPECTUS SUPPLEMENT (to Prospectus dated May 5, 2020) 4,848,485 Shares Merus N.V. Common Shares We are offering 4,848,485 common shares. Our common shares are listed on The Nasdaq Global Market under the symbol “MRUS.” On January 20, 2021, the last reported sale price of our common shares on The Nasdaq Global Ma |
|
| January 22, 2021 |
EX-1.1 Exhibit 1.1 Merus N.V. 4,848,485 Common Shares (nominal value €0.09 per share) Underwriting Agreement New York, New York January 21, 2021 Jefferies LLC SVB Leerink LLC As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: Merus N.V., a p |
|
| January 22, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 21, 2021 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organizati |
|
| January 21, 2021 |
S-3MEF As filed with the Securities and Exchange Commission on January 21, 2021 Registration No. |
|
| January 21, 2021 |
S-3/A As filed with the Securities and Exchange Commission on January 21, 2021 Registration No. |
|
| January 20, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Merus N.V. (Name of Issuer) Common shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) January 8, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 20, 2021 |
Joint Filing Agreement, dated January 20, 2021, among the Reporting Persons. EX-99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G with respect to the common shares of Merus N.V., nominal value €0.09 per share, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, and th |
|
| January 20, 2021 |
Termination of a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 20, 2021 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organizati |
|
| January 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 18, 2021 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organizati |
|
| January 19, 2021 |
$60,000,000 Merus N.V. Common Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-233367 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and accompanying |
|
| December 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Merus n.v. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) Maria E. Pasquale Executive Vice President and General Counsel Incyte Corporation 1801 Augustine Cut-Off, Wilmington, Delaware |
|
| November 10, 2020 |
MRUS / Merus N.V. / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) MERUS, N.V. (Name of Issuer) COMMON STOCK (Title of Class of Securities) N5749R100 (CUSIP Number) October 31, 2020 (Date of Event Which Requires Filing of this Statement) |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exac |
|
| November 5, 2020 |
Employment Agreement, dated August 20, 2020 between Peter Silverman and Merus N.V. Exhibit 10.3 EMPLOYMENT AGREEMENT THE EXECUTIVE between Peter B. Silverman as the Executive and Merus N.V. as the Company Exhibit 10.3 TABLE OF CONTENTS 1 DEFINITIONS AND INTERPRETATION 4 1.1 Definitions 4 1.2 Interpretation 4 2 EFFECTIVE DATE AND NOTICE PERIOD 5 2.1 Effective date 5 2.2 Notice period 5 3 EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT 5 4 TASKS, DUTIES AND NO |
|
| September 2, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 2, 2020 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organizat |
|
| September 2, 2020 |
EX-99.1 Exhibit 99.1 Closing In On Cancer September 2020Exhibit 99.1 Closing In On Cancer September 2020 Disclaimer This presentation (including any oral commentary that accompanies this marketable drugs; potential adverse public reaction to the use of cancer presentation) contains forward-looking statements within the meaning of immunotherapies; potential delays in enrollment of patients, which c |
|
| August 7, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2020 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organiza |
|
| August 7, 2020 |
Up to $75,000,000 Common Shares 424B5 1 d29978d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-233367 PROSPECTUS SUPPLEMENT (to Prospectus dated May 5, 2020) Up to $75,000,000 Common Shares We have entered into an Open Market Sale AgreementSM, or sales agreement, with Jefferies LLC, or Jefferies, relating to the sale of our common shares, nominal value €0.09 per share, offered by this pros |
|
| August 7, 2020 |
Open Market Sale Agreement, dated as of August 6, 2020, by and between Merus N.V. and Jefferies LLC EX-10.1 Exhibit 10.1 Execution Version OPEN MARKET SALE AGREEMENTSM August 6, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Merus N.V., a public limited liability company incorporated under the laws of the Netherlands (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sal |
|
| August 6, 2020 |
Merus N.V. Non-Executive Director Compensation Program Exhibit 10.1 Merus N.V. Non-Executive Director Compensation Program The non-executive directors (the “Non-Executive Directors” and each, a “Non-Executive Director”) of Merus N.V. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Executive Director Compensation Program (this “Program”). The compensation described in this Program shall be paid or be made, as applica |
|
| August 6, 2020 |
Consultancy Agreement, dated April 13, 2020, by and between the Registrant and Victor Sandor Exhibit 10.3 CONSULTANCY AGREEMENT This Consultancy Agreement (“Agreement”) is effective as of April 13, 2020 (the “Effective Date”) and is entered into by and between: (1) Merus US, Inc., a Delaware corporation (“Merus”); and (2) Victor Sandor, M.D. (“Consultant”); (Each of Merus and Consultant may hereinafter be referred to as a “Party” or collectively referred to as the “Parties.”) WHEREAS: (A) |
|
| August 6, 2020 |
Employment Agreement, dated July 2, 2020, by and among Merus US, Inc., the Registrant and Andrew Joe Exhibit 10.4 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated as of July 2, 2020, is made by and between Merus US, Inc., a Delaware corporation (together with any successors or assigns, the “Company”), and Andrew Joe (the “Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). RECITALS (A) It is the desire of the Company to |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exact nam |
|
| July 6, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2020 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organizat |
|
| June 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 6)1 Merus N.V. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) June 1, 2 |
|
| June 2, 2020 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 19, 2020 |
EX-99.1 May 2020 Closing In On Cancer Exhibit 99.1 Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statement |
|
| May 19, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2020 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organizati |
|
| May 14, 2020 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 11, 2020 |
Settlement Agreement, dated April 16, 2020, by and between the Registrant and Mark Throsby Final – Execution CopyExhibit 10.2 SETTLEMENT AGREEMENT THE UNDERSIGNED 1. Merus N.V., a public limited liability company (in Dutch: naamloze vennootschap), incorporated under the laws of the Netherlands, having its statutory seat at Utrecht, the Netherlands, registered with the Dutch Trade Register with number 30189136 (the Company); and 2. Mr. Mark Throsby, born in Adelaide on 22 March 1967, res |
|
| May 11, 2020 |
Non-Executive Director Compensation Program Exhibit 10.1 Merus N.V. Non-Executive Director Compensation Program The non-executive directors (the “Non-Executive Directors” and each, a “Non-Executive Director”) of Merus N.V. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Executive Director Compensation Program (this “Program”). The compensation described in this Program shall be paid or be made, as applica |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37773 MERUS N.V. (Exact na |
|
| April 30, 2020 |
POS AM Table of Contents As filed with the Securities and Exchange Commission on April 30, 2020 Registration No. |
|
| April 30, 2020 |
8-A12B/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A Amendment No. 1 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Merus N.V. (Exact name of registrant as specified in its charter) The Netherlands Not Applicable (State or other jurisdiction of Incorporation or organization) (I.R.S. Em |
|
| April 30, 2020 |
POS AM Table of Contents As filed with the Securities and Exchange Commission on April 30, 2020 Registration No. |
|
| April 29, 2020 |
10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 27, 2020 |
MRUS / Merus N.V. / Sofinnova Venture Partners IX, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Merus N.V. (Name of Issuer) Common Shares, €0.09 nominal value (Title of Class of Securities) N5749R100 (CUSIP Number) Nathalie Auber Sofinnova Investments, Inc. 3000 |
|
| April 24, 2020 |
MRUS / Merus N.V. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Merus N.V. (Name of Issuer) Common Shares, €0.09 nominal value per share (Title of Class of Securities) N5749R100 (CUSIP Number) April 16, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| April 16, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 15, 2020 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organiza |
|
| April 13, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 7, 2020 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organizat |
|
| March 17, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 17, 2020 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organiza |
|
| March 16, 2020 |
Exhibit 10.1.13 Execution Version EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement” ), dated as of December 16, 2019, is made by and between Merus US, Inc., a Delaware corporation (together with any successors or assigns, the “Company”), and Sven A. Lundberg, M.D. (the “ Executive” ) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). RECITAL |
|
| March 16, 2020 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2019, Merus N.V. (the “Company,” “we,” “us,” and “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares. Set forth below is a summary of certain information concer |
|
| March 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37773 MERUS N.V. (Exa |
|
| March 16, 2020 |
Settlement Agreement, dated December 11, 2019, by and between the Registrant and Ton Logtenberg Exhibit 10.1.12 SETTLEMENT AGREEMENT THE UNDERSIGNED 1. Merus N.V., a public limited liability company (in Dutch: naamloze vennootschap), incorporated under the laws of the Netherlands, having its statutory seat at Utrecht, the Netherlands, registered with the Dutch Trade Register with number 30189136 (the Company); and 2. Mr. T. Logtenberg, born on 22 July 1958, residing at Frans van Mierisstraat |
|
| March 12, 2020 |
EX-99.1 Exhibit 99.1 Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update UTRECHT, The Netherlands and CAMBRIDGE, Mass., March. 12, 2020 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced |
|
| March 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2020 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organiza |
|
| February 14, 2020 |
MRUS / Merus N.V. / Aquilo Capital Management, Llc Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* MERUS N.V. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 Merus N.V. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) December |
|
| February 14, 2020 |
MRUS / Merus N.V. / Baker Brothers Advisors LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2020 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2020 with respect to the Shares of Merus N.V., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act |
|
| February 14, 2020 |
MRUS / Merus N.V. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Merus N.V. (Name of Issuer) Common Shares, €0.09 nominal value per share (Title of Class of Securities) N5749R100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 9, 2020 |
EX-99.1 Closing In On Cancer January 9, 2020 Exhibit 99.1 Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking st |
|
| January 9, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2020 MERUS N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-37773 Not Applicable (State or other jurisdiction of incorporation or organiz |
|
| January 2, 2020 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-233383 EXPLANATORY NOTE As of January 1, 2020, Merus N.V., or the Company, commenced reporting as a domestic issuer under the Securities Exchange Act of 1934, as amended, or the Exchange Act. In connection with such reporting, the Company is filing this prospectus supplement as part of the Registration Statement on Form F-3 (File No. 333- |
|
| January 2, 2020 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-233367 EXPLANATORY NOTE As of January 1, 2020, Merus N.V., or the Company, commenced reporting as a domestic issuer under the Securities Exchange Act of 1934, as amended, or the Exchange Act. In connection with such reporting, the Company is filing this prospectus supplement as part of the Registration Statement on Form F-3 (File No. 333- |
|
| December 31, 2019 |
Minutes of the Extraordinary General Meeting of Merus N.V. EX-1 Exhibit 1 MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS MERUS N. |
|
| December 31, 2019 |
Results of the Extraordinary General Meeting of Merus N.V. EX-2 Exhibit 2 VOTING RESULTS OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS MERUS N. |
|
| December 31, 2019 |
MRUS / Merus N.V. 6-K - Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 Commission File Number: 001-37773 Merus N.V. (Translation of Registrant’s Name into English) Yalelaan 62 3584 CM Utrecht The Netherlands +31 85 016 2500 (Address of principal |
|
| December 16, 2019 |
EX-2 Exhibit 2 Works Council response to request Date of request December 9, 2019 Type of request: Request for Advice proposal/notification/consent Subject Proposed decision appointment of director Requester Russel G. |
|
| December 16, 2019 |
MRUS / Merus N.V. 6-K - Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 Commission File Number: 001-37773 Merus N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands +31 85 016 2500 (Address of principal |
|
| December 16, 2019 |
Proxy Card for Registered Holders of Merus N.V. EX-3 Exhibit 3 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the “Shareholder”). |
|
| December 16, 2019 |
EX-1 Exhibit 1 CONVENING NOTICE This is the convening notice for an extraordinary general meeting of shareholders of Merus N. |
|
| December 6, 2019 |
Minutes of the Extraordinary General Meeting of Merus N.V. EX-1 Exhibit 1 MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS MERUS N. |
|
| December 6, 2019 |
Results of the Extraordinary General Meeting of Merus N.V. EX-2 Exhibit 2 VOTING RESULTS OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS MERUS N.V. December 5, 2019 Shares represented at the meeting: 3,800,000 ordinary shares (~13.00% of the issued share capital). Agenda item For Against Abstain 1. Opening N/A N/A N/A 2. Amendment of articles of association 3,800,000 — — 3. Close N/A N/A N/A /s/ A. Noordzij A. Noordzij Secretary of the Meeting |
|
| December 6, 2019 |
Articles of Association of Merus N.V., as amended on December 5, 2019 EX-3 Exhibit 3 This is a translation into English of the official Dutch version of the articles of association of a limited liability company under Dutch law. |
|
| December 6, 2019 |
MRUS / Merus N.V. 6-K - Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 Commission File Number: 001-37773 Merus N.V. (Translation of Registrant’s Name into English) Yalelaan 62 3584 CM Utrecht The Netherlands +31 85 016 2500 (Address of principal |
|
| November 18, 2019 |
Proposed Articles of Association EX-2 Exhibit 2 This is a translation into English of the official Dutch version of the articles of association of a limited liability company under Dutch law. |
|
| November 18, 2019 |
Proxy Card for Registered Holders of Merus N.V. EX-3 Exhibit 3 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the “Shareholder”). |
|
| November 18, 2019 |
MRUS / Merus N.V. 6-K - Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2019 Commission File Number: 001-37773 Merus N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands +31 30 253 8800 (Address of principal |
|
| November 18, 2019 |
EX-1 Exhibit 1 CONVENING NOTICE This is the convening notice for an extraordinary general meeting of shareholders of Merus N. |
|
| November 14, 2019 |
MRUS / Merus N.V. / Medicxi Growth I Lp - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Merus N.V. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) November 8, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| November 14, 2019 |
EX-99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each |
|
| November 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Merus N.V. (Name of Issuer) Common Shares, nominal value €0.09 per share (Title of Class of Securities) N5749R100 (CUSIP Number) November |
|
| November 12, 2019 |
Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update EX-99.2 Exhibit 2 Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update UTRECHT, The Netherlands, and Cambridge, Mass., November 12, 2019 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage company developing innovative, full-length bispecific antibodies (Biclonics®), today announced financial results for the th |
|
| November 12, 2019 |
EX-99.1 Exhibit 1 Merus N.V. Unaudited Condensed Consolidated Statement of Financial Position Note September 30, 2019 December 31, 2018 (euros in thousands) Non-current assets Property, plant and equipment, net 3,422 2,420 Lease right-of-use assets 9 5,843 — Intangible assets, net 2,304 2,445 Non-current investments 5 10,609 16,945 Other assets 942 1,075 23,120 22,885 Current assets Trade and othe |
|
| November 12, 2019 |
MRUS / Merus N.V. 6-K - Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2019 Commission File Number: 001-37773 Merus N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands +31 30 253 8800 (Address of principal |
|
| November 8, 2019 |
MRUS / Merus N.V. / Cooperatief LSP IV U.A. - SC 13D/A Activist Investment SC 13D/A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Merus N.V. (Name of Issuer) Common Shares (Title of Class of Securities) N5749R100 (CUSIP Number) Ba |
|
| November 8, 2019 |
Lock-up Agreement Merus N.V. Public Offering of Common Shares EX-4 Exhibit 4 Lock-up Agreement Merus N.V. Public Offering of Common Shares November 4, 2019 Citigroup Global Markets Inc. Jefferies LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This letter (the “Lock-Up Agreement”) is being del |
|
| November 6, 2019 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION Merus N.V. 4,750,000 Common Shares (nominal value €0.09 per share) Underwriting Agreement New York, New York November 5, 2019 Citigroup Global Markets Inc. Jefferies LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 Lad |
|
| November 6, 2019 |
MRUS / Merus N.V. 6-K - Current Report of Foreign Issuer - 6-K 6-K 1 d803524d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2019 Commission File Number: 001-37773 Merus N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands +31 30 253 8800 |
|
| November 6, 2019 |
4,750,000 Shares Merus N.V. Common Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-233367 PROSPECTUS SUPPLEMENT 4,750,000 Shares Merus N.V. Common Shares We are selling 4,750,000 common shares. We have granted the underwriters an option to purchase up to 712,500 additional shares. Our common shares are listed on The Nasdaq Global Market under the symbol “MRUS.” The last reported sale price of our commo |
|
| November 5, 2019 |
Subject to completion, dated November 4, 2019 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-233367 The information in this prospectus supplement is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus supplement is not an offer to sell these securities, and we are not soliciting an offer |
|
| November 4, 2019 |
MRUS / Merus N.V. 6-K - Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2019 Commission File Number: 001-37773 Merus N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands +31 30 253 8800 (Address of principal |
|
| August 27, 2019 |
CORRESP August 27, 2019 VIA EDGAR TRANSMISSION Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| August 23, 2019 |
CORRESP August 23, 2019 VIA EDGAR TRANSMISSION Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| August 21, 2019 |
F-3 Table of Contents As filed with the Securities and Exchange Commission on August 21, 2019 Registration No. |
|
| August 20, 2019 |
F-3 Table of Contents As filed with the Securities and Exchange Commission on August 20, 2019 Registration No. |
|
| August 19, 2019 |
Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Update EX-99.2 Exhibit 2 Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Update UTRECHT, The Netherlands, August 19, 2019 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results fo |
|
| August 19, 2019 |
MRUS / Merus N.V. 6-K - Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2019 Commission File Number: 001-37773 Merus N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands +31 30 253 8800 (Address of principal e |
|
| August 19, 2019 |
EX-99.1 Exhibit 1 Merus N.V. Unaudited Condensed Consolidated Statement of Financial Position Note June 30, 2019 December 31, 2018 (euros in thousands) Non-current assets Property, plant and equipment, net 2,585 2,420 Lease right-of-use assets 9 6,069 — Intangible assets, net 2,351 2,445 Non-current investments 5 12,319 16,945 Other assets 742 1,075 24,066 22,885 Current assets Taxes and social se |
|
| July 31, 2019 |
MRUS / Merus N.V. 6-K - Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2019 Commission File Number: 001-37773 Merus N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht The Netherlands +31 30 253 8800 (Address of principal exec |
|
| July 31, 2019 |
EX-99.1 Exhibit 1 LEASE FOR OFFICE SPACE and other commercial space within the meaning of Article 7:230a of the Dutch Civil Code Model adopted by the Real Estate Council of the Netherlands (Raad voor Onroerende Zaken – ROZ) on 30 January 2015 and filed with the court registry of the District Court of The Hague on 17 February 2015, and registered there under number 15/20; also published on the webs |
|
| July 31, 2019 |
DATE 19 July 2019 DEVELOPMENT AGREEMENT Merus N.V. Genmab B.V. Kadans Science Partner XIII B.V. EX-99.2 Exhibit 2 English translation DATE 19 July 2019 DEVELOPMENT AGREEMENT between Merus N.V. and Genmab B.V. and Kadans Science Partner XIII B.V. CONTENTS 1. DEFINITIONS 3 2. STARTING POINTS 3 3. KEY OBLIGATIONS AND DURATION 4 4. DESIGN PHASE 5 5. ADDITIONAL COSTS / LESS COSTS 7 6. DEFINITIVE DESIGN ALTERATIONS 7 7. FIT-OUT PACKAGE 10 8. PLANNING / GRANTING OF PERMITS 13 9. IMPLEMENTATION PHAS |
|
| June 14, 2019 |
ARTICLES OF ASSOCIATION MERUS N.V. EX-99.3 Exhibit 3 This is a translation into English of the official Dutch version of the articles of association of a limited liability company under Dutch law. Definitions included in Article 1 below appear in the English alphabetical order, but will appear in the Dutch alphabetical order in the official Dutch version. In the event of a conflict between the English and Dutch texts, the Dutch tex |
|
| June 14, 2019 |
VOTING RESULTS OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS MERUS N.V. June 12, 2019 EX-99.2 Exhibit 2 VOTING RESULTS OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS MERUS N.V. June 12, 2019 Shares represented at the meeting: 15,201,857 ordinary shares (~65.00% of the issued share capital). Agenda item For Against Abstain 1. Opening N/A N/A N/A 2. Discussion annual report N/A N/A N/A 3. Implementation of compensation policy N/A N/A N/A 4. Adoption of annual accounts 15,201,857 — — 5 |
|
| June 14, 2019 |
MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS MERUS N.V. JUNE 12, 2019 EX-99.1 Exhibit 1 MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS MERUS N.V. JUNE 12, 2019 Minutes of the annual general meeting of shareholders of Merus N.V., a public limited liability company (naamloze vennootschap) incorporated under the laws of the Netherlands, having its corporate seat at Utrecht, the Netherlands (the “Company”), held on June 12, 2019 at 1:00 pm (CEST) at the offices o |
|
| June 14, 2019 |
MRUS / Merus N.V. 6-K - Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2019 Commission File Number: 001-37773 Merus N.V. (Translation of Registrants Name into English) Yalelaan 62 3584 CM Utrecht The Netherlands +31 30 253 8800 (Address of principal exec |
|
| May 30, 2019 |
MRUS / Merus N.V. 6-K - Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2019 Commission File Number: 001-37773 Merus N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands +31 30 253 8800 (Address of principal |
|
| May 30, 2019 |
Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update EX-99.2 Exhibit 2 Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update UTRECHT, The Netherlands, May 30, 2019 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results for th |
